Bristol-Myers Squibb (NYSE:BMY) Given News Impact Score of 0.16
Media headlines about Bristol-Myers Squibb (NYSE:BMY) have been trending somewhat positive on Wednesday, Accern reports. Accern ranks the sentiment of press coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Bristol-Myers Squibb earned a news impact score of 0.16 on Accern’s scale. Accern also assigned news stories about the biopharmaceutical company an impact score of 46.8805233578692 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
Here are some of the media headlines that may have impacted Accern Sentiment Analysis’s analysis:
- Bristol-Myers Squibb nixes 58 marketing jobs as HIV medications near patent cliff (fiercepharma.com)
- Bristol-Myers Squibb Co (NYSE:BMY) Shares Bought by Alley Co LLC (ismboard.com)
- Bristol-Myers Squibb Co (BMY) Position Maintained by Sit Investment Associates Inc (vothemes.com)
- Bristol-Myers Squibb Co (BMY) Shares Sold by Capital One National Association (famososartistas.com)
- Celldex (CLDX) Q2 Loss Narrows, Revenues Beat, Shares Up (finance.yahoo.com)
Several research firms recently commented on BMY. BidaskClub raised shares of Bristol-Myers Squibb from a “hold” rating to a “buy” rating in a report on Tuesday, June 27th. William Blair reaffirmed an “outperform” rating on shares of Bristol-Myers Squibb in a report on Monday, June 26th. Vetr raised shares of Bristol-Myers Squibb from a “buy” rating to a “strong-buy” rating and set a $64.33 price objective for the company in a report on Wednesday, July 26th. BMO Capital Markets downgraded shares of Bristol-Myers Squibb from a “market perform” rating to an “underperform” rating and set a $47.00 price objective for the company. in a report on Wednesday, May 3rd. Finally, Cowen and Company set a $65.00 price objective on shares of Bristol-Myers Squibb and gave the stock a “hold” rating in a report on Monday, July 10th. Two investment analysts have rated the stock with a sell rating, eleven have given a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the company. The stock currently has a consensus rating of “Hold” and an average target price of $63.33.
Shares of Bristol-Myers Squibb (NYSE BMY) traded up 0.86% during midday trading on Wednesday, reaching $57.40. 7,675,555 shares of the company’s stock were exchanged. Bristol-Myers Squibb has a 12-month low of $46.01 and a 12-month high of $63.65. The stock’s 50 day moving average is $55.66 and its 200-day moving average is $54.52. The stock has a market cap of $94.13 billion, a PE ratio of 20.96 and a beta of 1.17.
Bristol-Myers Squibb (NYSE:BMY) last issued its earnings results on Thursday, July 27th. The biopharmaceutical company reported $0.74 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.73 by $0.01. Bristol-Myers Squibb had a net margin of 22.66% and a return on equity of 32.33%. The company had revenue of $5.14 billion for the quarter, compared to analysts’ expectations of $5.09 billion. During the same period in the prior year, the business earned $0.69 EPS. The firm’s quarterly revenue was up 5.6% on a year-over-year basis. On average, equities analysts expect that Bristol-Myers Squibb will post $2.97 EPS for the current year.
The firm also recently announced a quarterly dividend, which was paid on Tuesday, August 1st. Shareholders of record on Friday, July 7th were issued a dividend of $0.39 per share. This represents a $1.56 annualized dividend and a yield of 2.72%. The ex-dividend date was Wednesday, July 5th. Bristol-Myers Squibb’s payout ratio is 56.73%.
In other Bristol-Myers Squibb news, Director Theodore R. Samuels II bought 6,000 shares of the company’s stock in a transaction on Wednesday, August 2nd. The shares were bought at an average cost of $55.94 per share, for a total transaction of $335,640.00. Following the acquisition, the director now directly owns 18,000 shares in the company, valued at $1,006,920. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.23% of the stock is owned by corporate insiders.
COPYRIGHT VIOLATION WARNING: This report was reported by Daily Political and is the sole property of of Daily Political. If you are reading this report on another website, it was illegally copied and reposted in violation of US & international trademark and copyright laws. The original version of this report can be accessed at https://www.dailypolitical.com/2017/08/09/bristol-myers-squibb-nysebmy-given-news-impact-score-of-0-16.html.
About Bristol-Myers Squibb
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
Receive News & Ratings for Bristol-Myers Squibb Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Company and related companies with MarketBeat.com's FREE daily email newsletter.